

# Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07290569

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Oruka Therapeutics, Inc.
Enrollment	160 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Participants ≥ 18 years of age
- Have a diagnosis of plaque psoriasis for > 6 months
- Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and

... and 3 more (see full listing online)

### Exclusion (5)

- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study

## Locations (26 total)

---

Oruka Therapeutics Investigative Site, Phoenix, Arizona, United States  
Oruka Therapeutics Investigative Site, North Little Rock, Arkansas, United States  
Oruka Therapeutics Investigative Site, Los Angeles, California, United States  
... and 23 more locations